BioCryst Pharmaceuticals, Inc. presented additional analyses of the APeX-1 trial of BCX7353 for the prevention of attacks in patients with HAE at the annual congress of the European Academy of Allergy and Clinical Immunology (EAACI) 26-30 May 2018 in Munich, Germany.
“These additional analyses of our Phase 2 APeX-1 trial of once-daily oral BCX7353 provide further details regarding pharmacokinetics, safety, and effects on target enzyme (plasma kallikrein) inhibition as well as measures of quality of life and symptoms of stress, anxiety, and depression in patients with HAE,” said Dr. William Sheridan, SVP and Chief Medical Officer of BioCryst Pharmaceuticals. “The APeX-1 trial results formed the basis of our ongoing double-blind randomized Phase 3 trial, APeX-2, comparing 2 dose levels of daily BCX7353 to placebo. We remain on track to report the results of APeX-2 in the first half of 2019.”
Copies of the four posters are available at www.biocryst.com.
(Source: BioCryst)
